Drugs / ExPlas
last change Sep 2021 re-read 3 minutes ago

ExPlas

Developed for
Alzheimer disease
Investigated by
Norwegian University of Science and Technology · St. Olavs Hospital

Trials 1

202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05068830 Sep 2021 → Mar 2027 expected Alzheimer disease Norwegian University of Science and Technology Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ExPlas ClinicalTrials.gov intervention name — accepted as the source's own label NCT05068830 ↗
Route Intravenous “Dosage form: Solution for intravenous infusion” NCT05068830 ↗